ClinicalTrials.gg
CompletedNCT01270828Updated Jan 28, 2021Results posted

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

A Phase 3 interventional study of Pregabalin and placebo in Post Herpetic Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 146 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
806
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.

Enrollment
Largest of 15
806 · median 126
Started
2011
with 1 other
Phase 3
5 of 15
1 open now
Registered
9th of 15
by date
Lead sponsor
7 of 15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one has the largest enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 9th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing pregabalin in Neuralgia, Postherpetic, or all of them as a file.
02

Study summary

The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)

03

Conditions studied

  • Post Herpetic Neuralgia

Keywords

  • Control Release Pregabalin in Post Herpetic Neuralgia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have pain present for more than 3 months after the healing of the herpes zoster skin rash.
  • At screening (V1) and enrollment (V2), patients must have a score of greater than or equal to 4 on the Pain Numeric Rating Scale (1 week recall period).
  • At enrollment (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be greater than or equal to 4.
  • Male or female of any race, at least 18 years of age, and using appropriate methods of

Exclusion criteria

Exclusion Criteria:

  • \<30 mL/min (estimated from serum creatinine).
  • Skin conditions in the affected dermatome that could alter sensation
  • Pregabalin use in the last 30 days. Subjects taking pregabalin in the last 30 days should be washed out of pregabalin for at least 30 days prior to screening visit. Patients who had not responded to pregabalin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
806 participants (actual)

Study arms

  • Experimental
    Pregablain CR tablet 82.5 to 660mg

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks

  • Drugplacebo

    Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Loss of Therapeutic Response.

    Loss of Therapeutic Response (LTR) is defined as \<30% pain response relative to the single blind phase baseline or patient discontinuation due to lack of efficacy or adverse events in the double blind phase of the study. For the calculation of \<30% pain response relative to baseline, baseline will be defined as the mean of the last 7 observations prior to the start of SB treatment, which will be compared with the 7 days rolling average of pain response in DB phase. Participants may be discontinued due to lack of efficacy in this study at the discretion of the study physician.

    Time frame: 13 Weeks

Secondary outcomes

  1. Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results

    A secondary LTR endpoint (S-LTR) was defined as the 5 day rolling average pain score during DB, compared to the 5 day randomization baseline pain score. As a secondary endpoint, S-LTR was defined as: 1. At least a 30% increase in the 5 days rolling average pain score during DB relative to the 5 Day randomization baseline pain score 2. A 5 days rolling average pain score ≥4. Participants who discontinue due to lack of efficacy or adverse events in the DB phase of the study will also be counted as an LTR.

    Time frame: 13 Weeks

  2. Percentage of Participants With 30% Reduction in the Mean Pain Score.

    The 30% pain responders were defined as participants with at least a 30% reduction in the mean pain score from SB baseline to DB endpoint.

    Time frame: 13 Weeks

  3. Percentage of Participants With 50% Reduction in the Mean Pain Score.

    The 50% pain responders were defined as participants with at least a 50% reduction in the mean pain score from SB baseline to DB endpoint.

    Time frame: 13 Weeks

  4. Change From Baseline to Endpoint in Weekly Mean Pain Score.

    The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain

    Time frame: SB Baseline (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19

  5. Change in the Weekly NRS-Pain (1-Week Recall).

    The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. Participants were asked to rate their pain over the past week.

    Time frame: SB Baseline (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19

  6. Change in the Medical Outcomes Study-Sleep Scale (MOS-SS).

    The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute.

    Time frame: SB Baseline (BL) (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19

  7. Change in the MOS-SS-Quantity of Sleep.

    The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The item "Quantity of sleep" of MOS-SS is presented here.

    Time frame: SB Baseline (BL) (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19

  8. The MOS-SS-Optimal Sleep.

    The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The optimal sleep score is a dichotomous 'Yes' or 'No' rating, where 'Yes' indicates optimal sleep (average 7-8 hours per night) and 'No' indicates not optimal sleep. The "percentage of participants with optimal sleep" is presented here.

    Time frame: Week 6 and Week 19

  9. Percentage of Participants With Change in the Patient Global Impression of Change (PGIC) Score

    The PGIC is a participant-rated instrument that has been used in chronic pain and fibromyalgia studies to rate change in a patient's overall status. This single item instrument uses a 7 point Likert scale, anchored by (1) very much improved, to (7) very much worse.

    Time frame: Week 19

  10. Change in the Short Form 36 Health Survey (SF-36)

    The SF 36 is a self administered, validated questionnaire that measures each of the following 8 health aspects: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception over the past week. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) where, higher scores indicate a better health related quality of life.

    Time frame: Week 19

  11. Change in Mean Daily Sleep Interference Scores

    The pain related sleep interference item rating scale is scored on an 11 point numeric rating scale (NRS Sleep). It is self administered by the subject in order to rate how pain has interfered with their sleep during the past 24 hours, ranging from 0 (pain does not interfere with sleep) to 10 (completely interferes (unable to sleep due to pain)). Participants are to describe how their pain has interfered with their sleep during the past 24 hours by choosing the appropriate number on the numeric rating scale.

    Time frame: Week 19

  12. Change in Hospital Anxiety and Depression Scales (HADS)

    The HADS is a self administered questionnaire that was designed to screen for the presence of a mood disorder in medically ill patients. To distinguish psychiatric presentations from physical illness, the items focus on subjective disturbance of mood rather than physical signs. The HADS contains 14 items rated on 4 point Likert type scales. Two subscales assess depression and anxiety. Each subscale consists of 7 statements, rated on a scale of 0 to 3 (0 = No anxiety or depression, to 3 = Severe feelings of anxiety or depression). Separate scores are calculated for each subscale ranging from 0 to 21. Higher scores denote greater severity of depression or anxiety

    Time frame: Week 19

  13. Change in the Brief Pain Inventory (BPI-sf)

    The BPI sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI sf consists of 5 questions. Questions 1, 2, 3, and 4 measure pain on an 11 point scale from 0 (no pain) to 10 (worst pain possible). Question 5 consists of 7 item subsets which measure the level of interference of pain on daily functions on an 11 point scale from 0 (Does not interfere) to 10 (Completely interferes).

    Time frame: Week 19

  14. Percentage of Participants With Benefit From Treatment, Satisfaction With Treatment and Willingness to Continue Treatement (BSW)

    The BSW is administered by the study physician or designated site personnel and consists of three single item measures designed to capture the patient's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.

    Time frame: Week 19

  15. Number of Participants With Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A serious adverse event is any untoward medical occurrence at any dose that: Results in death; Is life-threatening (immediate risk of death); Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or Results in congenital anomaly/birth defect. The study physician used the adjective "severe" to those AEs that interfere significantly with participant's usual function.

    Time frame: Baseline to Week 20

  16. Percentage of Participants With Suicidal Behaviour/Ideation

    Percentage of participants with suicidal behavior/ideation were noted as Baseline, Weeks 6, 11, 15, 19 and 20.

    Time frame: Baseline, Weeks 6, 11, 15, 19 and 20

07

Results

Posted Jan 13, 2016

Participant flow

A total of 129 centers in 17 countries screened subjects for the study, including 68 in the US, 6 in Bulgaria, 6 in Poland, 6 in Russia, 6 in the Ukraine, 5 in India, 5 in South Africa, 5 in Sweden, 4 in Slovakia, 3 in Colombia, 3 in Croatia, 3 in Germany, 2 in Denmark, 2 in Hong Kong, 2 in Serbia, 2 in Taiwan, and 1 in the Czech Republic.

Pregabalin CR SB
Participant flow — Pregabalin CR SB
MilestonePregabalin Controlled Release (CR) DBPlacebo DBPregabalin CR SB
Started00806
Completed00660
Not completed00146
Withdrew: Reason unspecified008
Withdrew: Enrolled but not treated005
Withdrew: Related adverse event0046
Withdrew: Lack of efficacy0032
Withdrew: Withdrawal by subject0029
Withdrew: Lost to follow-up0010
Withdrew: Unrelated ae008
Withdrew: Protocol violation008
Double Blind Phase
Participant flow — Double Blind Phase
MilestonePregabalin Controlled Release (CR) DBPlacebo DBPregabalin CR SB
Started2082050
Completed1821600
Not completed26450
Withdrew: Death010
Withdrew: Protocol violation010
Withdrew: Protocol and gcp non-compliance430
Withdrew: Reason unspecified740
Withdrew: Withdrawal by subject6150
Withdrew: Lost to follow-up120
Withdrew: Lack of efficacy2110
Withdrew: Adverse event not related to study drug110
Withdrew: Adverse event related to study drug570

Outcome measures

PrimaryNumber of Participants With Loss of Therapeutic Response.

Loss of Therapeutic Response (LTR) is defined as \<30% pain response relative to the single blind phase baseline or patient discontinuation due to lack of efficacy or adverse events in the double blind phase of the study. For the calculation of \<30% pain response relative to baseline, baseline will be defined as the mean of the last 7 observations prior to the start of SB treatment, which will be compared with the 7 days rolling average of pain response in DB phase. Participants may be discontinued due to lack of efficacy in this study at the discretion of the study physician.

Time frame:
13 Weeks
Reported as:
Number · Participants
Number of Participants With Loss of Therapeutic Response.
ParticipantsPregabalin CR DBPlacebo DB
Number of Participants With Loss of Therapeutic Response.2963
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Log Rank · p = <0.0001
SecondaryParticipants With Secondary LTR Based on 5 Day Rolling Average Diary Results

A secondary LTR endpoint (S-LTR) was defined as the 5 day rolling average pain score during DB, compared to the 5 day randomization baseline pain score. As a secondary endpoint, S-LTR was defined as: 1. At least a 30% increase in the 5 days rolling average pain score during DB relative to the 5 Day randomization baseline pain score 2. A 5 days rolling average pain score ≥4. Participants who discontinue due to lack of efficacy or adverse events in the DB phase of the study will also be counted as an LTR.

Time frame:
13 Weeks
Reported as:
Number · Participants
Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results
ParticipantsPregabalin CR DBPlacebo DB
Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results4987
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Log Rank · p = <0.0001
SecondaryPercentage of Participants With 30% Reduction in the Mean Pain Score.

The 30% pain responders were defined as participants with at least a 30% reduction in the mean pain score from SB baseline to DB endpoint.

Time frame:
13 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With 30% Reduction in the Mean Pain Score.
Percentage of participantsPregabalin CR DBPlacebo DB
Percentage of Participants With 30% Reduction in the Mean Pain Score.95.683.8
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Chi-squared · p = <0.0001
SecondaryPercentage of Participants With 50% Reduction in the Mean Pain Score.

The 50% pain responders were defined as participants with at least a 50% reduction in the mean pain score from SB baseline to DB endpoint.

Time frame:
13 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With 50% Reduction in the Mean Pain Score.
Percentage of participantsPregabalin CR DBPlacebo DB
Percentage of Participants With 50% Reduction in the Mean Pain Score.88.368.6
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Chi-squared · p = <0.0001
SecondaryChange From Baseline to Endpoint in Weekly Mean Pain Score.

The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain

Time frame:
SB Baseline (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Endpoint in Weekly Mean Pain Score.
Units on a scalePregabalin CR DBPlacebo DB
SB Baseline to Week 19-4.89 ± 0.12-3.95 ± 0.12
DB Baseline to Week 19-0.04 ± 0.110.87 ± 0.11
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -0.94 · 95% CI -1.26 to -0.62
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -0.91 · 95% CI -1.21 to -0.61
SecondaryChange in the Weekly NRS-Pain (1-Week Recall).

The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. Participants were asked to rate their pain over the past week.

Time frame:
SB Baseline (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Reported as:
Least squares mean · Units on a scale
Change in the Weekly NRS-Pain (1-Week Recall).
Units on a scalePregabalin CR DBPlacebo DB
SB Baseline to Week 19-5.0 ± 0.13-3.9 ± 0.14
DB Baseline to Week 19-0.1 ± 0.130.9 ± 0.13
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -1.1 · 95% CI -1.47 to -0.75
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -1.0 · 95% CI -1.34 to -0.65
SecondaryChange in the Medical Outcomes Study-Sleep Scale (MOS-SS).

The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute.

Time frame:
SB Baseline (BL) (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Reported as:
Least squares mean · Units on a scale
Change in the Medical Outcomes Study-Sleep Scale (MOS-SS).
Units on a scalePregabalin CR DBPlacebo DB
Sleep Problems Index I-SB BL to wk 19(N=202,195)-19.9 ± 1.09-16.7 ± 1.13
Sleep Problems Index I-DB BL to wk 19(N=202,195)1.2 ± 1.054.4 ± 1.09
SleepProblems Index II-SB BL to wk 19(N=202,195)-21.2 ± 1.07-17.4 ± 1.11
SleepProblems Index II-DB BL to wk 19(N=202,194)0.2 ± 1.014.3 ± 1.05
Sleep Disturbance-SB BL to wk 19-28.3 ± 1.42-21.1 ± 1.48
Sleep Disturbance-DB BL to wk 19-1.1 ± 1.317.6 ± 1.36
Snoring-SB BL to wk 19(N=202,194)-3.3 ± 1.57-4.7 ± 1.64
Snoring-DB BL to wk 19(N=201,194)-0.6 ± 1.410.8 ± 1.46
Awaken short of breath/headache-SB BL to wk 19-11.9 ± 1.21-10.4 ± 1.26
Awaken short of breath/headache-DB BL to wk 19-1.2 ± 1.23-0.2 ± 1.27
Sleep adequacy-SB BL to wk 1919.9 ± 1.8317.5 ± 1.90
Sleep adequacy-DB BL to wk 19(N=202,195)-3.3 ± 1.82-6.0 ± 1.89
Somnolence-SB BL to wk 19(N=202,195)-12.0 ± 1.19-12.0 ± 1.23
Somnolence-DB BL to wk 19(N=203,194)-0.7 ± 1.15-0.9 ± 1.19
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0324 · Mean difference (final values): -3.2 · 95% CI -6.1 to -0.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0223 · Mean difference (final values): -3.3 · 95% CI -6.1 to -0.5
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0098 · Mean difference (final values): -3.8 · 95% CI -6.6 to -0.9
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0033 · Mean difference (final values): -4.0 · 95% CI -6.7 to -1.4
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0002 · Mean difference (final values): -7.3 · 95% CI -11.1 to -3.5
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -8.7 · 95% CI -12.2 to -5.2
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.5264 · Mean difference (final values): 1.4 · 95% CI -2.8 to 5.6
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.4520 · Mean difference (final values): -1.4 · 95% CI -5.2 to 2.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.3714 · Mean difference (final values): -1.5 · 95% CI -4.7 to 1.8
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.5639 · Mean difference (final values): -1.0 · 95% CI -4.2 to 2.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.3223 · Mean difference (final values): 2.5 · 95% CI -2.4 to 7.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.2742 · Mean difference (final values): 2.7 · 95% CI -2.2 to 7.6
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.9816 · Mean difference (final values): 0.0 · 95% CI -3.2 to 3.1
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.9282 · Mean difference (final values): 0.1 · 95% CI -2.9 to 3.2
SecondaryChange in the MOS-SS-Quantity of Sleep.

The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The item "Quantity of sleep" of MOS-SS is presented here.

Time frame:
SB Baseline (BL) (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Reported as:
Least squares mean · Hours
Change in the MOS-SS-Quantity of Sleep.
HoursPregabalin CR DBPlacebo DB
Quantity of sleep-SB BL to wk 19(N=203,192)0.9 ± 0.090.7 ± 0.10
Quantity of sleep-DB BL to wk 19(N=202,192)-0.1 ± 0.08-0.4 ± 0.09
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.1635 · Mean difference (final values): 0.2 · 95% CI -0.1 to 0.4
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0363 · Mean difference (final values): 0.2 · 95% CI 0.0 to 0.5
SecondaryThe MOS-SS-Optimal Sleep.

The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The optimal sleep score is a dichotomous 'Yes' or 'No' rating, where 'Yes' indicates optimal sleep (average 7-8 hours per night) and 'No' indicates not optimal sleep. The "percentage of participants with optimal sleep" is presented here.

Time frame:
Week 6 and Week 19
Reported as:
Number · Percentage of participants
The MOS-SS-Optimal Sleep.
Percentage of participantsPregabalin CR DBPlacebo DB
Week 6 (N=208,205)58.7 ± 0.0962.4 ± 0.10
Week 19 (N=204,197)54.9 ± 0.0854.8 ± 0.09
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Chi-squared · p = 0.432
  • Pregabalin CR DB vs Placebo DB · Chi-squared · p = 0.987
SecondaryPercentage of Participants With Change in the Patient Global Impression of Change (PGIC) Score

The PGIC is a participant-rated instrument that has been used in chronic pain and fibromyalgia studies to rate change in a patient's overall status. This single item instrument uses a 7 point Likert scale, anchored by (1) very much improved, to (7) very much worse.

Time frame:
Week 19
Reported as:
Number · Percentage of participants
Percentage of Participants With Change in the Patient Global Impression of Change (PGIC) Score
Percentage of participantsPregabalin CR DBPlacebo DB
Very much improved31.523.1
Much improved36.930.3
Minimally improved16.719.0
No change10.312.8
Minimally worse2.57.2
Much worse1.57.2
Very much worse0.50.5
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Regression, Logistic · p = 0.0007 · Odds ratio (or): 1.85 · 95% CI 1.30 to 2.65Odds ratio is the probability of the event occurring in Pregabalin DB relative to the event occurring in Placebo DB. Odds ratio \> 1 is in favor of Pregabalin DB.
  • Pregabalin CR DB vs Placebo DB · Regression, Logistic · p = 0.0009 · Odds ratio (or): 2.32 · 95% CI 1.41 to 3.81Odds ratio is the probability of the event occurring in Pregabalin DB relative to the event occurring in Placebo DB. Odds ratio \> 1 is in favor of Pregabalin DB.
SecondaryChange in the Short Form 36 Health Survey (SF-36)

The SF 36 is a self administered, validated questionnaire that measures each of the following 8 health aspects: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception over the past week. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) where, higher scores indicate a better health related quality of life.

Time frame:
Week 19
Reported as:
Least squares mean · Units on a scale
Change in the Short Form 36 Health Survey (SF-36)
Units on a scalePregabalin CR DBPlacebo DB
Physical Component-SB BL to wk 19(N=202,195)7.5 ± 0.545.6 ± 0.56
Physical Component-DB BL to wk 19(N=202,195)0.1 ± 0.51-2.3 ± 0.53
Mental Component-SB BL to wk 19(N=202,195)6.4 ± 0.625.5 ± 0.64
Mental Component-DB BL to wk 19(N=202,195)-1.1 ± 0.62-2.2 ± 0.64
Physical functioning-SB BL to wk 1911.7 ± 1.448.9 ± 1.49
Physical functioning-DB BL to wk 19-1.4 ± 1.25-4.9 ± 1.29
Role-Physical-SB BL to wk 1918.9 ± 1.6213.9 ± 1.67
Role-Physical-DB BL to wk 19-2.4 ± 1.54-7.7 ± 1.60
Bodily pain-SB BL to wk 1931.0 ± 1.5123.6 ± 1.56
Bodily pain-DB BL to wk 191.4 ± 1.38-6.2 ± 1.43
General Health Perception-SB BL to wk19(N=202,195)11.3 ± 1.058.2 ± 1.08
General Health Perception-DB BL to wk19(N=202,195)1.4 ± 0.96-4.0 ± 1.00
Vitality-SB BL to wk 19(N=202,195)13.7 ± 1.2510.7 ± 1.30
Vitality-DB BL to wk 19(N=202,195)-3.5 ± 1.21-6.5 ± 1.25
Social Functioning-SB BL to wk 1918.5 ± 1.3515.7 ± 1.39
Social Functioning-DB BL to wk 19-2.1 ± 1.28-4.3 ± 1.32
Role-Emotional-SB BL to wk 1915.0 ± 1.4311.6 ± 1.47
Role-Emotional-DB BL to wk 19-1.4 ± 1.42-5.4 ± 1.47
Mental Health-SB BL to wk 19(N=202,195)11.1 ± 1.059.5 ± 1.08
Mental Health-DB BL to wk 19(N=202,195)-1.3 ± 1.04-3.7 ± 1.08
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0003 · Mean difference (final values): 7.4 · 95% CI 3.4 to 11.5
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): 7.7 · 95% CI 4.0 to 11.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0275 · Mean difference (final values): 3.2 · 95% CI 0.4 to 6.0
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): 5.4 · 95% CI 2.8 to 8.0
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0735 · Mean difference (final values): 3.0 · 95% CI -0.3 to 6.4
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0684 · Mean difference (final values): 3.0 · 95% CI -0.2 to 6.2
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.1197 · Mean difference (final values): 2.8 · 95% CI -0.7 to 6.4
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.2210 · Mean difference (final values): 2.1 · 95% CI -1.3 to 5.5
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0847 · Mean difference (final values): 3.3 · 95% CI -0.5 to 7.1
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0365 · Mean difference (final values): 4.0 · 95% CI 0.3 to 7.8
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.2749 · Mean difference (final values): 1.6 · 95% CI -1.2 to 4.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0806 · Mean difference (final values): 2.5 · 95% CI -0.3 to 5.2
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0082 · Mean difference (final values): 2.0 · 95% CI 0.5 to 3.4
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0008 · Mean difference (final values): 2.3 · 95% CI 1.0 to 3.7
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.2097 · Mean difference (final values): 0.9 · 95% CI -0.8 to 2.5
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.1669 · Mean difference (final values): 1.2 · 95% CI -0.5 to 2.8
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.1466 · Mean difference (final values): 2.8 · 95% CI -1.0 to 6.7
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0439 · Mean difference (final values): 3.4 · 95% CI 0.1 to 6.7
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0250 · Mean difference (final values): 4.9 · 95% CI 0.6 to 9.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0107 · Mean difference (final values): 5.4 · 95% CI 1.3 to 9.5
SecondaryChange in Mean Daily Sleep Interference Scores

The pain related sleep interference item rating scale is scored on an 11 point numeric rating scale (NRS Sleep). It is self administered by the subject in order to rate how pain has interfered with their sleep during the past 24 hours, ranging from 0 (pain does not interfere with sleep) to 10 (completely interferes (unable to sleep due to pain)). Participants are to describe how their pain has interfered with their sleep during the past 24 hours by choosing the appropriate number on the numeric rating scale.

Time frame:
Week 19
Reported as:
Least squares mean · Units on a scale
Change in Mean Daily Sleep Interference Scores
Units on a scalePregabalin CR DBPlacebo DB
SB Baseline to Week 19 (N=205,203)-4.5 ± 0.11-3.5 ± 0.11
DB Baseline to Week 19 (N=206,204)-0.2 ± 0.100.7 ± 0.10
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -0.9 · 95% CI -1.23 to -0.64
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -0.9 · 95% CI -1.12 to -0.58
SecondaryChange in Hospital Anxiety and Depression Scales (HADS)

The HADS is a self administered questionnaire that was designed to screen for the presence of a mood disorder in medically ill patients. To distinguish psychiatric presentations from physical illness, the items focus on subjective disturbance of mood rather than physical signs. The HADS contains 14 items rated on 4 point Likert type scales. Two subscales assess depression and anxiety. Each subscale consists of 7 statements, rated on a scale of 0 to 3 (0 = No anxiety or depression, to 3 = Severe feelings of anxiety or depression). Separate scores are calculated for each subscale ranging from 0 to 21. Higher scores denote greater severity of depression or anxiety

Time frame:
Week 19
Reported as:
Least squares mean · Units on a scale
Change in Hospital Anxiety and Depression Scales (HADS)
Units on a scalePregabalin CR DBPlacebo DB
HADS-Anxiety-SB Baseline to Week 19-1.8 ± 0.21-1.1 ± 0.21
HADS-Anxiety-DB Baseline to Week 190.1 ± 0.190.9 ± 0.20
HADS-Depression-SB Baseline to Week 19-1.8 ± 0.20-1.2 ± 0.21
HADS-Depression-DB Baseline to Week 190.2 ± 0.190.8 ± 0.19
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0154 · Mean difference (final values): -0.7 · 95% CI -1.2 to -0.1
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0027 · Mean difference (final values): -0.8 · 95% CI -1.3 to -0.3
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0166 · Mean difference (final values): -0.7 · 95% CI -1.2 to -0.1
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = 0.0217 · Mean difference (final values): -0.6 · 95% CI -1.1 to -0.1
SecondaryChange in the Brief Pain Inventory (BPI-sf)

The BPI sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI sf consists of 5 questions. Questions 1, 2, 3, and 4 measure pain on an 11 point scale from 0 (no pain) to 10 (worst pain possible). Question 5 consists of 7 item subsets which measure the level of interference of pain on daily functions on an 11 point scale from 0 (Does not interfere) to 10 (Completely interferes).

Time frame:
Week 19
Reported as:
Least squares mean · Units on a scale
Change in the Brief Pain Inventory (BPI-sf)
Units on a scalePregabalin CR DBPlacebo DB
Pain Severity Index-SB Baseline to Week 19-18.0 ± 0.47-13.8 ± 0.49
Pain Severity Index-DB Baseline to Week 19-0.7 ± 0.433.1 ± 0.44
Pain Interference Index-SB Baseline to Week 19-21.9 ± 0.71-17.2 ± 0.74
Pain Interference Index-DB Baseline to Week 19-0.2 ± 0.674.0 ± 0.70
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -4.2 · 95% CI -5.5 to -3.0
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -3.8 · 95% CI -5.0 to -2.7
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -4.6 · 95% CI -6.5 to -2.7
  • Pregabalin CR DB vs Placebo DB · ANCOVA · p = <0.0001 · Mean difference (final values): -4.2 · 95% CI -6.0 to -2.4
SecondaryPercentage of Participants With Benefit From Treatment, Satisfaction With Treatment and Willingness to Continue Treatement (BSW)

The BSW is administered by the study physician or designated site personnel and consists of three single item measures designed to capture the patient's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.

Time frame:
Week 19
Reported as:
Number · Percentage of participants
Percentage of Participants With Benefit From Treatment, Satisfaction With Treatment and Willingness to Continue Treatement (BSW)
Percentage of participantsPregabalin CR DBPlacebo DB
Benefit from treatment98.593.3
Satisfaction with treatment96.090.7
Willingness to continue treatment87.681.3
Statistical analysis
  • Pregabalin CR DB vs Placebo DB · Regression, Logistic · p = 0.0161 · Odds ratio (or): 4.77 · 95% CI 1.34 to 17.00Odds ratio was the probability of the event occurring in pregabalin CR DB relative to the event occurring in placebo DB. Odds ratio \> 1 was in favor of pregabalin CR.
  • Pregabalin CR DB vs Placebo DB · Regression, Logistic · p = 0.0378 · Odds ratio (or): 2.48 · 95% CI 1.05 to 5.85Odds ratio was the probability of the event occurring in pregabalin CR DB relative to the event occurring in placebo DB. Odds ratio \> 1 was in favor of pregabalin CR.
  • Pregabalin CR DB vs Placebo DB · Regression, Logistic · p = 0.0901 · Odds ratio (or): 1.61 · 95% CI 0.93 to 2.81Odds ratio was the probability of the event occurring in pregabalin CR DB relative to the event occurring in placebo DB. Odds ratio \> 1 was in favor of pregabalin CR.
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A serious adverse event is any untoward medical occurrence at any dose that: Results in death; Is life-threatening (immediate risk of death); Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or Results in congenital anomaly/birth defect. The study physician used the adjective "severe" to those AEs that interfere significantly with participant's usual function.

Time frame:
Baseline to Week 20
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsPregabalin CR DBPlacebo DBPregabalin CR SB
Participants with AEs8063441
Participants with Serious AEs7317
Participants with Severe AEs9335
SecondaryPercentage of Participants With Suicidal Behaviour/Ideation

Percentage of participants with suicidal behavior/ideation were noted as Baseline, Weeks 6, 11, 15, 19 and 20.

Time frame:
Baseline, Weeks 6, 11, 15, 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants With Suicidal Behaviour/Ideation
Percentage of participantsPregabalin CR DBPlacebo DB
SB BL(N=208,205)00.5
Week 6 (N=208,205)00
Week 11 (N=194,178)00
Week 15 (N=183,167)00
Week 19 (N=204,197)00
Week 20 (N=199,194)00

Adverse events

Collected over Baseline to Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin CR DB—7/208 (3.4%)7/208 (3.4%)
Placebo DB—3/205 (1.5%)1/205 (0.5%)
Pregabalin CR SB—17/801 (2.1%)202/801 (25.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPregabalin CR DBPlacebo DBPregabalin CR SB
ThrombocytopeniaBlood and lymphatic system disorders0/2081/2050/801
BronchopneumoniaInfections and infestations0/2081/2050/801
Cerebrovascular disorderNervous system disorders0/2081/2050/801
Anaemia of chronic diseaseBlood and lymphatic system disorders1/2080/2050/801
Cardiac failureCardiac disorders1/2080/2050/801
Acute sinusitisInfections and infestations1/2080/2050/801
Perirectal abscessInfections and infestations1/2080/2050/801
Back painMusculoskeletal and connective tissue disorders1/2080/2050/801
SciaticaNervous system disorders1/2080/2050/801
Renal massRenal and urinary disorders1/2080/2050/801
Most frequent other events
Most frequent other events
EventPregabalin CR DBPlacebo DBPregabalin CR SB
DizzinessNervous system disorders7/2081/205137/801
SomnolenceNervous system disorders1/2080/20591/801

Baseline characteristics

Baseline analysis population description consisted of all participants randomized to the DB phase who received at least 1 dose of study medication in the DB phase (full analysis set).

Age, Customized
Age, Customized(Participants)Pregabalin CR DBPlacebo DBTotal
<18 years000
18-44 years262450
45-64 years8678164
≥65 years96103199
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin CR DBPlacebo DBTotal
Female134122256
Male7483157
08

Study locations

146 sites
  • Fundamental Research
    Gulf Shores, Alabama 36542, United States
  • Radiant Research, Inc.
    Chandler, Arizona 85224, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • HOPE Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85027, United States
  • Genova Clinical Research
    Tucson, Arizona 85704, United States
  • Larry Watkins, M.D. (Private Practice)
    Little Rock, Arkansas 72205, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72205, United States
  • Hearne Family Practice Clinic
    Little Rock, Arkansas 72206, United States
  • Center for Clinical Research, Inc
    Carmichael, California 95608, United States
  • Community Medical Providers
    Clovis, California 93611, United States
  • Sierra Medical Research
    Clovis, California 93612, United States
  • Inland Pain Medicine
    Colton, California 92324, United States
  • The Helm Center
    Laguna Hills, California 92637, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • USC IDS Pharmacy
    Los Angeles, California 90089, United States
  • Translational Research Group, Inc
    North Hollywood, California 91606, United States
  • George J. Rederich, M.D., Incorporated
    Redondo Beach, California 90277, United States
  • Integrated Research Group, Inc.
    Riverside, California 92506, United States
  • Drug Shipmnent Only Aristotelis T. Laliotis, M.D. Integrated Research Center, Inc.
    San Diego, California 92117, United States
  • Integrated Research Center, Inc.
    San Diego, California 92117, United States
  • Center For Clinical Research, Inc.
    San Francisco, California 94115, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • Foothills Pain Management Clinic, PS
    West Covina, California 91790, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33472, United States
  • Innovative Research of West Florida, Inc.
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33916, United States
  • Health Care Family Rehab & Research Center
    Hialeah, Florida 33012, United States
  • Laszlo Jozsef Mate, MD
    North Palm Beach, Florida 33408, United States
  • Family Care Specialists
    Ocala, Florida 34471, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Comprehensive Pain care of South Florida
    Royal Palm Beach, Florida 33411, United States
  • Comprehensive Clinical Development Inc.
    Saint Petersburg, Florida 33716, United States
  • Neurology Clinical Research, Inc.
    Sunrise, Florida 33351, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Injury Care Medical Center
    Boise, Idaho 83713, United States
  • Millennium Pain Center, LLC
    Bloomington, Illinois 61701, United States
  • (IP Shipping Address) Advocate Illinois Masonic Medical Center
    Chicago, Illinois 60657, United States
  • Chicago Anesthesia Pain Specialists
    Chicago, Illinois 60657, United States
  • Advanced Pain Care Clinic
    Evansville, Indiana 47714, United States
  • Clinical Research Advantage
    Evansville, Indiana 47714, United States
  • Global Scientific Innovations
    Evansville, Indiana 47714, United States
  • Clinical Trials of America, Inc.
    Monroe, Louisiana 71201, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02135, United States
  • Beacon Clinical Research
    Brockton, Massachusetts 02301, United States
  • Infinity Medical Research, Inc.
    North Dartmouth, Massachusetts 02747, United States
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • QUEST Research Institute
    Bingham Farms, Michigan 48025, United States
  • The Center for Pharmaceutical Research, PC
    Kansas City, Missouri 64114, United States
  • Medex Healthcare Research, Inc.
    Saint Louis, Missouri 63117, United States
  • Clinvest, A Division of Banyan Group, Inc
    Springfield, Missouri 65807, United States
  • Montana Medical Research Inc
    Missoula, Montana 59808, United States
  • Lincoln Internal Medicine Associates
    Lincoln, Nebraska 68516, United States
  • Drug Shipment Only: Heartland Clinical Research, Inc.
    Omaha, Nebraska 68134, United States
  • Heartland Clinical Research, Inc.
    Omaha, Nebraska 68134, United States
  • The Office of Dr. Stephen H. Miller, MD
    Las Vegas, Nevada 89144, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurological Institute
    Amherst, New York 14226, United States
  • SPRI Clinical Trials LLC
    Brooklyn, New York 11235, United States
  • Medex Healthcare Research, Inc - Saint Louis
    New York, New York 10036, United States
  • North American Partners In Pain Management
    New York, New York 11580, United States
  • Asheville Neurology Specialists, PA
    Asheville, North Carolina 28806, United States
  • Raleigh Neurology Associates, P.A.
    Raleigh, North Carolina 27607, United States
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Radiant Research
    Akron, Ohio 44311, United States
  • Providence Health Partners-Center for Clinical Research
    Dayton, Ohio 45439, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Mark A Fisher
    Oklahoma City, Oklahoma 73112, United States
  • Pharmacorp Clinical Trials, Inc.
    Charleston, South Carolina 29412, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • Lovelace Scientific Resources, Inc.
    Austin, Texas 78758, United States
  • Radiant Research
    Dallas, Texas 75231, United States
  • ClinRx Research, LLC
    Richardson, Texas 75080, United States
  • Hillcrest Family Health Centers, Division of Clinical Research
    Waco, Texas 76710, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
  • Clinical Investigation Specialists, Inc.
    Kenosha, Wisconsin 53142, United States
  • DCC "St. Pantaleimon" OOD
    Pleven, 5800, Bulgaria
  • MHAT-Pleven
    Pleven, 5800, Bulgaria
  • MBALNP "Sveti Naum" EAD, Klinika po nervni bolesti za dvigatelni narushenia
    Sofia, 1113, Bulgaria
  • Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie ¿ Sofia, AD, Sofia, Nevrologichno otdelenie
    Sofia, 1202, Bulgaria
  • MBAL "Tokuda Bolnitsa", Otdelenie po nevrologiya
    Sofia, 1407, Bulgaria
  • Universitetska mnogoprofilna bolnitsa za aktivno lechenie Aleksandrovska, Klinika po Nevrologia
    Sofia, 1431, Bulgaria
  • Reumalab S.A.S
    Medellin, Antioquia, Colombia
  • Centro de Investigacion y Atencion Para la Salud Mental S.A. - CESAME
    Bogota, Cundinamarca 0, Colombia
  • Fundacion Cardiovascular de Colombia
    Floridablanca, Santander 0, Colombia
  • Opca bolnica Karlovac
    Karlovac, Karlovacka Županija 47000, Croatia
  • Klinicki Bolnicki Centar Osijek
    Osijek, Osjecko-baranjska Županija 31000, Croatia
  • Opca bolnica "Dr. Ivo Pedisic"
    Sisak, Sisacko-moslavacka Županija 44000, Croatia
  • Neurologicka ambulance
    Prerov I, 750 02, Czechia
  • Aalborg Sygehus Nord
    Aalborg, Region Nordjylland DK-900, Denmark
  • Glostrup Hospital
    Glostrup, DK-2066, Denmark
  • Schmerzzentrum Frankfurt
    Frankfurt/Main, Hessen 60311, Germany
  • pro scientia med im MARE Klinikum
    Kiel-Kronshagen, Schleswig-Holstein 24119, Germany
  • DGS-Schmerzzentrum Eichstätt
    Eichstaett, 85072, Germany

Showing the first 100 of 146 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Huffman CL, Goldenberg JN, Weintraub J, Sanin L, Driscoll J, Yang R, Chew ML, Scavone JM. Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial. Clin J Pain. 2017 Jul;33(7):569-578. doi: 10.1097/AJP.0000000000000445. PubMed 27753650 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Sep 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2011
First posted
Jan 5, 2011
Start
Mar 2011
Primary completionActual
Sep 2014
CompletionActual
Nov 2014
Results first posted
Jan 13, 2016
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01270828
Responsible party
Sponsor
First posted
Jan 5, 2011
Start date
Mar 2011
Primary completion
Sep 2014
Completion
Nov 2014
Results posted
Jan 13, 2016
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion